Observations placeholder
Jevtana
Identifier
019229
Type of Spiritual Experience
Background
A description of the experience
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor.
Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
On Jan, 2, 2016: 266 people reported to have side effects when taking Jevtana. Among them, 4 people (1.50%) have Hallucination.
Time on Jevtana when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Dec, 30, 2015: 266 people reported to have side effects when taking Jevtana. Among them, 52 people (19.55%) have Death.
Time on Jevtana when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |